DYAI — Dyadic International Share News
0.000.00%
Last trade - 00:00- $15.99m
- $17.91m
- $3.09m
U.S. STOCKS ON THE MOVE-SiriusPoint, Nutex Health, Barrick Gold
U.S. STOCKS ON THE MOVE-SiriusPoint, Shopify, Gold miners
Dyadic International up on expanded vaccine deal for African markets
Brief: Dyadic Announces Expanded Licensing Agreement To Develop And Commercialize Vaccines And Biologics For African Continent
Dyadic International Inc reports results for the quarter ended in December - Earnings Summary
Brief: Dyadic Reports 2022 Year End Results
Dyadic International Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Dyadic Provides Phase 1 Clinical Trial Update For Its Dyai-100 Covid-19 Recombinant Protein Rbd Booster Vaccine Candidate
Brief: Dyadic Announces Initiation Of Dosing Of First-In-Human Phase 1 Trial To Demonstrate Clinical Safety And Antibody Response In Humans For Dyai-100 Covid-19 Recombinant Protein Rbd Booster Vaccine Candidate
Brief: Dyadic International Announces Sale Of Equity Interest In Alphazyme
Dyadic International Inc reports results for the quarter ended in September - Earnings Summary
Brief: Dyadic International Inc Reports Q3 Loss Per Share Of $0.06
Dyadic International Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Dyadic Receives Regulatory Approval To Initiate Phase 1 Clinical Trial
Dyadic International Inc reports results for the quarter ended in June - Earnings Summary
Brief: Dyadic Reports Second Quarter 2022 Financial Results And Highlights Recent Company Developments
Dyadic International Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Dyadic Announces Research, License And Collaboration For Manufacture Of Animal Free Ingredients
Dyadic International Inc expected to post a loss of 8 cents a share - Earnings Preview